This is a preview of subscription content, log in via an institution to check access.
References
Foust, K.D. et al. Nat. Biotechnol. 27, 59–65 (2009).
Ek, C.J. et al. J. Comp. Neurol. 460, 451–464 (2003).
Ek, C.J. et al. J. Comp. Neurol. 496, 13–26 (2006).
Lowenstein, P.R. Nat. Biotechnol. 27, 42–44 (2009).
Caley, W.D. & Maxwell, D.S. J. Comp. Neurol. 138, 31–48 (1970).
Saunders, N.R. et al. in Developmental Neurotoxicology (eds. Harry, J. & Tilson, H.) (Informa Health Care, New York, 2009).
Saunders, N.R. Handbook Exper. Pharmacol. 103, 327–369 (1992).
Saunders, N.R. et al. Trends Neurosci. 31, 279–286 (2008).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Saunders, N., Joakim Ek, C. & Dziegielewska, K. The neonatal blood-brain barrier is functionally effective, and immaturity does not explain differential targeting of AAV9. Nat Biotechnol 27, 804–805 (2009). https://doi.org/10.1038/nbt0909-804
Issue Date:
DOI: https://doi.org/10.1038/nbt0909-804
- Springer Nature America, Inc.
This article is cited by
-
The deletion of mutant SOD1 via CRISPR/Cas9/sgRNA prolongs survival in an amyotrophic lateral sclerosis mouse model
Gene Therapy (2020)
-
Brainstem development requires galactosylceramidase and is critical for pathogenesis in a model of Krabbe disease
Nature Communications (2020)
-
MiR-298 Counteracts Mutant Androgen Receptor Toxicity in Spinal and Bulbar Muscular Atrophy
Molecular Therapy (2016)
-
Distinct transduction profiles in the CNS via three injection routes of AAV9 and the application to generation of a neurodegenerative mouse model
Molecular Therapy - Methods & Clinical Development (2014)
-
Several rAAV Vectors Efficiently Cross the Blood–brain Barrier and Transduce Neurons and Astrocytes in the Neonatal Mouse Central Nervous System
Molecular Therapy (2011)